J Korean Ophthalmol Soc.  2024 Jul;65(7):435-441. 10.3341/jkos.2024.65.7.435.

One-year Clinical Outcome of Topical Bromfenac in Central Serous Chorioretinopathy

• Kwon MS
• Kim YM
• Kim JY
• Do JR
• Kang YK
• Park DH

• KMID: 2557621
• DOI: http://doi.org/10.3341/jkos.2024.65.7.435

Abstract

Purpose
To evaluate the efficacy of topical bromfenac in treating central serous chorioretinopathy (CSC) over a 1-year period.
Methods
A retrospective analysis was conducted on 57 patients (57 eyes) with CSC followed for > 1 year. Patients were divided into two groups: those treated with bromfenac eye drops twice daily (29 eyes) and a control group (28 eyes). Best-corrected visual acuity (BCVA), central macular thickness (CMT), and subretinal fluid (SRF) height were measured and compared between the two groups as was the proportion of chronic cases.
Results
Significant improvements in CMT and SRF height were noted in both groups over the follow-up period. The bromfenac group demonstrated significantly lower CMT at 6, 9, and 12 months (p = 0.045, 0.042, and 0.023, respectively) and lower SRF height (p = 0.037, 0.048, and 0.046, respectively) compared to the control group. The proportion of chronic cases was significantly lower in the bromfenac group (17.2%) compared to the control group (42.9%, p = 0.035).
Conclusions
Topical bromfenac reduced the rate of progression to chronic CSC and showed significant anatomical improvements after 6 months, suggesting its potential as an effective treatment option.

Keyword

Bromfenac, Central serous chorioretinopathy